Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 664

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 664
---
 2024, OmnigenicsAI Corp, Heritas Ltd., and MultiplAI Health Ltd. signed a binding term sheet outlining the terms and conditions for a Reseller License Agreement to settle MultiplAI Ltd.’s outstanding debt to Heritas Ltd, amounting to US$395,260, due by February 2025. As part of the agreement, MultiplAI Ltd. will grant OmnigenicsAI Corp, exclusive rights to commercialize its proprietary blood -basedscreening tests in Latin America, along with providing 600 pre -paidtests for business development purposes during the term of three years starting on January 1 st, 2025. These exclusive rights are granted for a period of five years, commencing on January 1, 2025. As of December 31, 2024, the contribution has not been made. In addition, the Group is evaluating the recoverability of said license and products in light of the conditions necessary to commercialize such products in the territory defined in the contract, within the period established therein.

F-118 Notes to Unaudited Interim Condensed Combined Financial Statements (Amounts in US Dollars, except otherwise indicated) 24.Events after the reporting period Management has considered subsequent events through May30, 2025, which is the date in which these unaudited interim condensed combined financial statements were issued. New Disbursement under existing loan agreements In connection with the credit agreements with CIBIC and Bioceres described in note20, and to support ongoing operations, the subsidiary Heritas S.A.U. received financing from these credit facilities after December31, 2024, totaling $178,006: •$81,996 of financing from Bioceres S.A. On March18, 2025, Heritas Argentina amended its existing loans agreements with Bioceres S.A. to extend the two available credit lines (see note20, b), Bioceres “Line 1” and “Line 2”) from a total of $977,147 to $1,157,143. This implies that, as of the date of issuance of these interim condensed combined financial statements, $142,231 of said total amount of the credit lines are still available); and •$96,010 of financing from CIBIC, of which a) $9,087 were obtained using available credit lines (see note20, b), CIBIC “Line 1” and “Line 2”), and b) $86,923 correspond to an additional